- Firefly Neuroscience (NASDAQ: AIFF) signs a new commercial agreement with Heidelberg University Hospital.
- Utilizes FDA-cleared BNA™ Platform for analyzing EEG data in a study on 15q13.3 CNVs.
- Study involves 30 subjects and runs through 2026, expanding Firefly's licensing strategy.
Firefly Neuroscience, Inc. (NASDAQ: AIFF) has announced a significant commercial agreement with the Institute of Human Genetics at Heidelberg University Hospital. This partnership will leverage Firefly's FDA-cleared BNA™ Platform in a pioneering neuroscience study examining the neurophysiological impact of 15q13.3 copy number variants (CNVs).
The study will involve the analysis of EEG data from 30 subjects—15 with deletions and 15 with duplications of the 15q13.3 chromosomal region. This research is expected to run through 2026, aiming to identify electrophysiological biomarkers and characterize neurocognitive profiles associated with these genetic variations.
Firefly will provide EEG systems, training, and comprehensive analytical support throughout the study. The results will be compared against Firefly's proprietary FDA-cleared normative database, which is central to their BNA™ platform's analytical capabilities.
This collaboration not only represents an expansion of Firefly’s licensing business but also builds on previous successful partnerships with Prof. Dr. med. Christian Schaaf. By aligning with a prestigious institution like Heidelberg University Hospital, Firefly enhances its scientific credibility and opens avenues for further research and commercial opportunities.
The project is expected to yield novel insights into the brain's functional architecture in rare genetic conditions, offering potential advancements in the diagnosis and treatment of neurodevelopmental disorders. Firefly's focus on developing innovative solutions for brain health underscores their commitment to transforming neurodiagnostic capabilities and expanding their market reach globally.
